Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group
Authors:
- 1 March 2006
- journal article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 1 (3) , 211-217
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An UpdateThe Oncologist, 2004
- An Advance in Small-Cell Lung Cancer Treatment--More or LessJNCI: Journal of the National Cancer Institute, 2003
- A Phase II Study of Topotecan in Patients with Relapsed Small-Cell Lung CancerClinical Lung Cancer, 2003
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- 126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II studyLung Cancer, 1997
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.Journal of Clinical Oncology, 1996
- Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1995
- Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.Journal of Clinical Oncology, 1994
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI: Journal of the National Cancer Institute, 1993